FDA Ties Brisdelle Approval To Unmet Need For Hormone-Free Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
In an NEJM perspective piece, agency reviewers explain why they believed Noven’s paroxetine for treating hot flashes should come to market despite only “modest” efficacy and an advisory committee’s overwhelming recommendation against approval.
You may also be interested in...
Placebo Effect Raises Questions About Clinical Value For Depomed, Noven Hot Flash Treatments
Advisory Committee for Reproductive Health Drugs asks whether FDA standards are too difficult to meet for non-hormonal products like gabapentin and paroxetine after the placebo arms of both drugs’ trials show a strong reduction in vasomotor symptoms.
Gabapentin Cannot Navigate Efficacy Hurdles At Advisory Committee
FDA Advisory Committee on Reproductive Health Drugs votes overwhelmingly against recommending approval of new indication for severe to moderate vasomotor symptoms, saying the modest effect shown was not sufficient.
Tighter REMS For Zohydro ER Still Insufficient For FDA Advisory Panel
FDA’s Anesthetic and Analgesic Drug Products Advisory Committee wants Risk Evaluation and Mitigation Strategies enhanced for all extended-release/long-acting opioids as it recommends 11-2, one abstention, against approval of Zogenix’s single-entity hydrocodone product.